Editor's Recommendations
Most Read Articles
one year ago
Cannabinoid hyperemesis syndrome (CHS) should be regarded as an important differential diagnosis in recurrent nausea and vomiting, according to a retrospective cohort study .
Jackey Suen, one year ago
Several biomarker candidates may improve screening and monitoring of treatment response in colorectal cancer (CRC), inflammatory bowel disease (IBD) and hepatocellular carcinoma (HCC), say experts of the Department of Medicine and Therapeutics, Chinese University of Hong Kong (CUHK), at the CUHK’s Advances in Medicine 2015 conference.
one year ago
The Drug Control Authority (DCA) of Malaysia has approved a new indication for the long-acting somatostatin analogue lanreotide. This new indication is for the treatment of grade 1 and low grade 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs)—of midgut, pancreatic or unknown origin except the hindgut—in adult patients with unresectable locally advanced or metastatic disease.
one year ago
In an exclusive interview with MIMS Doctor, renowned gastroenterologists from Subang Jaya Medical Centre, Dr Tan Soon Seng and Dr Ranjeev C K Prabhakeran,
shared their perspectives and experiences on the use of Fuse® (Full Spectrum Endoscopy) in their clinical practice. Both of them have been practicing gastroenterology
for almost 20 years and have completed more than 1,200 procedures using the Fuse® system.

Fuse® has been available in Malaysia since January 2015. Subang Jaya Medical Centre is the first medical centre in Asia and the ONLY one in Malaysia to use the
Fuse® at the present moment. As cited in The Lancet Oncology,1 March 2014, Fuse® Endoscopy System detected 69% more pre-cancerous polyps than standard forwardviewing colonoscopy.